{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:44:06Z","timestamp":1789811046878,"version":"4.0.1"},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T00:00:00Z","timestamp":1489104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The efficacy of mogamulizumab in adult T\u2010cell leukemia\/lymphoma (<jats:styled-content style=\"fixed-case\">ATLL<\/jats:styled-content>) was reported in a previous phase 2 study. Compared with patients in clinical trials, however, most patients in real\u2010life settings have demonstrated worse outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>We retrospectively analyzed 96 patients with relapsed\/refractory <jats:styled-content style=\"fixed-case\">ATLL<\/jats:styled-content> who received mogamulizumab treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Relapsed\/refractory <jats:styled-content style=\"fixed-case\">ATLL<\/jats:styled-content> patients with a median age of 70\u00a0years received a median of five courses of mogamulizumab. Hematologic toxicity and skin rash were the most common adverse events, and both were manageable. Of 96 patients, 87 were evaluable for efficacy. The overall response rate was 36%, and the median progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) and overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) from the start of mogamulizumab therapy were 1.8 and 4.0\u00a0months, respectively. Of the original 96 patients, only 25 fulfilled the inclusion criteria of the phase 2 study. Those who met the criteria demonstrated longer median <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> durations of 2.7 and 8.5\u00a0months, respectively. The median <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> from diagnosis in relapsed\/refractory <jats:styled-content style=\"fixed-case\">ATLL<\/jats:styled-content> patients receiving mogamulizumab was 12\u00a0months, longer than the 5.8\u00a0months in a historical cohort without mogamulizumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In clinical practice, mogamulizumab exhibited antitumor activity in patients with relapsed\/refractory <jats:styled-content style=\"fixed-case\">ATLL<\/jats:styled-content>, with an acceptable toxicity profile. Mogamulizumab therapy improved the <jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content> of <jats:styled-content style=\"fixed-case\">ATLL<\/jats:styled-content> patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12863","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T16:29:48Z","timestamp":1486052988000},"page":"501-507","source":"Crossref","is-referenced-by-count":18,"title":["Effects of mogamulizumab in adult T\u2010cell leukemia\/lymphoma in clinical practice"],"prefix":"10.1111","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-3451","authenticated-orcid":false,"given":"Masaaki","family":"Sekine","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kubuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Kameda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Koga General Hospital  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Toyama","sequence":"additional","affiliation":[{"name":"Miyazaki Prefectural Nobeoka Hospital  Nobeoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriaki","family":"Kawano","sequence":"additional","affiliation":[{"name":"Miyazaki Prefectural Miyazaki Hospital  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Miyakonojo Medical Center  Miyakonojo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Fujimoto Genral Hospital  Miyakonojo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junzo","family":"Ishizaki","sequence":"additional","affiliation":[{"name":"Miyazaki Aisenkai Nichinan hospital  Nichinan Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawano","sequence":"additional","affiliation":[{"name":"Koga General Hospital  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Kamiunten","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Akizuki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Tahira","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruko","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Shide","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kitanaka","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine Kawasaki Medical School  Kurashiki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"Miyazaki Prefectural Miyazaki Hospital  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Koga General Hospital  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hematology Faculty of Medicine University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,10]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V50.3.481.481"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_5_4_1","first-page":"281","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.9958"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702731"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0632-0"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1505"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3575"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13338"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-012-1146-2"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.55.6312"},{"key":"e_1_2_5_15_1","first-page":"31","article-title":"A multicenter retrospective study of mogamulizumab efficacy in adult T\u2010Cell leukemia\/lymphoma","volume":"17","author":"Iyama S","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.2428"},{"key":"e_1_2_5_17_1","unstructured":"Institute NC.Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). NIH.https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40. Accessed May 29 2009."},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/23495"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.2101"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12962"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12863","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:54:32Z","timestamp":1696366472000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,10]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/ejh.12863"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12863","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,10]]}}}